The American Society for Bone and Mineral Research developed 13 clinical recommendations (7 primary and 6 secondary) to address the undertreatment of osteoporosis-related fractures and prevent secondary fracture among persons aged ≥65 years with hip or vertebral fractures.
The diagnosis of osteoporosis was overrepresented in patients receiving high-dose and underrepresented in patients receiving low-dose statin treatment.
A meta-analysis found that teriparatide and denosumab may be the most efficacious therapy for prevention of glucocorticoid-induced vertebral fractures.
The study, presented at the American Society for Bone and Mineral Research 2019 Annual Meeting, described the experience of patients who initiated treatment with abaloparatide.
Researchers sought to assess the ability of the Fracture Risk Assessment Tool to discriminate between women who do and do not experience major osteoporotic fractures.
Researchers assessed the effect of genetically predicted higher serum calcium levels on bone mineral density and the risk for fracture, using Mendelian randomization.
Researchers investigated the safety and efficacy of twice-weekly 28.2 μg teriparatide compared with once-weekly 56.5 μg teriparatide in Japanese patients with osteoporosis.
Red cell distribution width, a measure of the amount of variability in the size of red blood cells, is routinely assessed in blood counts and may accurately predict risk for hip fracture.
Screening and treatment of osteoporosis is statistically lower in black Americans, which may be related to the differences in fracture outcomes according to race.
Patients with greater BMD improvement after 1 year of denosumab are more likely to lose BMD after the transition to alendronate therapy in the second year.
